secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0000872589-26-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut
--------------------------------------------------------------------------------

- Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.
- EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.
- Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.
- New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.
- FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/0000872589-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/regn-20260429.htm
  HTML page:      https://secwatch.observer/filing/0000872589-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer